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Structured Abstract 42 
Background 43 
High-risk coronary atherosclerotic plaque is associated with higher plasma troponin 44 
concentrations suggesting ongoing myocardial injury that may be a target for dual antiplatelet 45 
therapy. 46 
Objectives 47 
To determine whether ticagrelor reduces high-sensitivity troponin I concentrations in patients 48 
with established coronary artery disease and high-risk coronary plaque. 49 
Methods 50 
In a randomized double-blind placebo-controlled trial, patients with multivessel coronary 51 
artery disease underwent coronary 18F-fluoride positron emission tomography-computed 52 
tomography and measurement of high-sensitivity cardiac troponin I and were randomized 53 
(1:1) to ticagrelor 90 mg twice daily or matched placebo. The primary endpoint was troponin 54 
I concentration at 30 days in patients with increased coronary 18F-fluoride uptake. 55 
Results 56 
In total, 202 patients were randomized and 191 met the pre-specified criteria for inclusion in 57 
the primary analysis. In patients with increased coronary 18F-fluoride uptake (n=120/191) 58 
there was no evidence that ticagrelor had an effect on plasma troponin concentrations at 30 59 
days (ratio of geometric means for ticagrelor versus placebo, 1.11, [95% confidence interval 60 
0.90 to 1.36], p=0.32). Over 1 year, ticagrelor had no effect on troponin concentrations in 61 
patients with increased coronary 18F-fluoride uptake (ratio of geometric means, 0.86, 95% 62 
confidence interval 0.63 to 1.17, p=0.33). 63 
Conclusions 64 
 3 
Dual antiplatelet therapy with ticagrelor does not reduce plasma troponin concentrations in 65 
patients with high-risk coronary plaque, suggesting that subclinical plaque thrombosis does 66 
not contribute to ongoing myocardial injury in this setting. 67 
 68 
Clinical Trials.gov Study ID: NCT02110303 69 
 70 
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Condensed Abstract 73 
In a double-blind randomized placebo-controlled trial, 191 patients with multivessel coronary 74 
artery disease underwent 18F-fluoride positron emission tomography and computed 75 
tomography coronary angiography. In patients with high-risk plaque defined by 18F-fluoride 76 
uptake in at least one coronary plaque (n=120/191), there was no evidence that dual 77 
antiplatelet therapy with ticagrelor affected 30-day plasma troponin concentrations (ratio of 78 
geometric means 1.11 [95% confidence interval 0.90-1.36], p=0.32). This suggests that 79 
subclinical plaque thrombosis does not contribute to ongoing myocardial injury in patients 80 
with multivessel coronary artery disease and higher risk plaque. 81 
  82 
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List of Abbreviations 83 
ECG – Electrocardiogram 84 
MBq - Megabecquerel 85 
PET-CCTA – Positron emission tomography – Coronary computed tomography angiography 86 
PLATO – PLATelet inhibition and patients Outcomes Trial 87 
SUVMAX – maximum standardized uptake value 88 
TBR – Tissue to background ratio  89 
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Introduction 90 
Coronary plaque rupture is the commonest cause of acute coronary thrombosis and 91 
myocardial infarction (1). Patients who have an increased risk of recurrent plaque rupture 92 
events may benefit from intensification of secondary prevention therapy (2). In this regard, 93 
the addition of a P2Y12 receptor antagonist to low-dose aspirin reduces the risk of 94 
cardiovascular death, myocardial infarction and stroke in patients with recent (3) or prior (4) 95 
myocardial infarction. Ticagrelor is an oral reversible antagonist of the platelet adenosine 96 
diphosphate P2Y12 receptor. It provides faster, more potent and more consistent P2Y12 97 
inhibition than clopidogrel (5). In the PLATelet inhibition and patients Outcomes (PLATO) 98 
trial of 18,624 patients presenting with acute coronary syndrome, ticagrelor was superior to 99 
clopidogrel for the prevention of cardiovascular events and death (3). Moreover, the 100 
prolonged use of dual antiplatelet therapy following myocardial infarction continues to 101 
reduce cardiovascular events, albeit at the expense of increased rates of major bleeding (4). 102 
Thus, there is a clinical need to improve the risk stratification of patients to enable physicians 103 
to better select ‘vulnerable’ patients who may benefit from extended duration of dual 104 
antiplatelet therapy.  105 
 106 
A novel approach for assessing patients at high-risk of coronary plaque rupture is using 107 
positron emission tomography and coronary computed tomography angiography (PET-108 
CCTA). This technique uses the radiotracer 18F-fluoride to identify regions of increased 109 
disease activity in coronary artery plaques. Previous studies have demonstrated that coronary 110 
18F-fluoride uptake correlates with a high-risk cardiovascular profile and identifies ruptured 111 
coronary plaques in patients with recent myocardial infarction (6, 7). Importantly, we have 112 
previously reported an association between increased coronary 18F-fluoride uptake and 113 
higher plasma high-sensitivity cardiac troponin I concentrations in patients with stable 114 
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coronary artery disease (7). Silent plaque rupture is common and subclinical plaque thrombus 115 
formation is a frequent incidental post-mortem finding in patients with multivessel coronary 116 
artery disease who have died from non-cardiovascular causes (8). This suggests that coronary 117 
18F-fluoride uptake may identify high-risk plaque that is associated with thrombus formation 118 
and subclinical myocardial injury from microemboli. If correct, this would potentially be 119 
modifiable with intensive dual antiplatelet therapy. 120 
 121 
In this study, we assessed whether coronary 18F-fluoride activity identifies patients with 122 
stable multivessel coronary artery disease who respond favorably to ticagrelor as assessed by 123 
a reduction in high-sensitivity cardiac troponin I concentrations. 124 




Study Design 128 
This was an investigator-initiated double-blind randomized parallel-group placebo-controlled 129 
trial conducted at a single centre in Edinburgh, UK. The study was approved by the local 130 
institutional review board, the Scottish Research Ethics Committee (REC reference: 131 
14/SS/0089), Medicines and Healthcare products Regulatory Agency, and the United 132 
Kingdom (UK) Administration of Radiation Substances Advisory Committee. It was 133 
performed in accordance with the Declaration of Helsinki. All patients provided written 134 
informed consent prior to any study procedures. 135 
 136 
Study Population 137 
Patients were recruited between March 2015 and March 2017. Patients were included if they 138 
met the following criteria: age ≥40 years and already receiving aspirin therapy with 139 
angiographically proven multivessel coronary artery disease defined as at least two major 140 
epicardial vessels with any combination of either (a) >50% luminal stenosis, or (b) previous 141 
revascularization (percutaneous coronary intervention or coronary artery bypass graft 142 
surgery). Patients were excluded if they had any of the following criteria: an acute coronary 143 
syndrome within the last 12 months, any ongoing indication for dual anti-platelet therapy, or 144 
concurrent thienopyridine (clopidogrel or prasugrel) or oral anticoagulant therapy, or 145 
percutaneous coronary intervention or coronary artery bypass graft surgery within the last 3 146 
months. Full eligibility criteria are provided in the Supplementary Table 1. 147 
  148 
 9 
Trial Intervention and Randomization 149 
Patients were randomly assigned 1:1 to either ticagrelor 90 mg twice daily or matched 150 
placebo tablets (AstraZeneca, UK). Randomization was performed using a web-based system 151 
that ensured allocation concealment, with treatment allocation incorporating minimization 152 
based on age (<65, ≥65 years old), sex, baseline plasma high-sensitivity troponin I 153 
concentration (≤5.1, >5.1 ng/L) and the presence or absence of coronary 18F-fluoride uptake. 154 
A random element was included with a 1 in 10 chance of the determined treatment allocation 155 
being switched to the other treatment arm. 156 
 157 
Study Procedures 158 
All patients underwent a baseline assessment to confirm eligibility and measurement of 159 
plasma high-sensitivity cardiac troponin I concentration and platelet-monocyte aggregates. 160 
An electrocardiogram (ECG) gated 18F-fluoride PET-CTCA was performed after patients 161 
had received 50-100 mg of oral metoprolol if their resting heart rate was >65 beats/min prior 162 
to the intravenous administration of 250 MBq 18F-fluoride. After 60 min, patients were 163 
imaged with a hybrid PET-CT scanner (64-multidetector Biograph mCT, Siemens Medical 164 
Systems, Erlangen, Germany). Attenuation correction CT scans were performed prior to the 165 
acquisition of ECG-gated list-mode PET data using a single 30-min bed position centred on 166 
the heart. Finally, an ECG-gated CCTA was performed in mid-diastole during held expiration 167 
following sublingual glyceryl trinitrate.  168 
 169 
Image Analysis 170 
Positron emission tomography images were reconstructed in diastole (50-75% of the R-R 171 
interval, 2 iterations, 21 subsets Siemens Ultra-HD algorithm) and fused with contrast 172 
enhanced CCTA. Analysis of the CT images was performed using dedicated software (Vitrea 173 
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Advanced, Toshiba Systems) with multi-planar reformatting for plaque analysis as required. 174 
Coronary arteries with a diameter ≥2 mm were assessed according to the 18-segment Society 175 
of Cardiac Computed Tomography model. Qualitative and semi-quantitative analysis of the 176 
PET images was performed by trained observers using an OsiriX workstation (OsiriX version 177 
3.5.1 64-bit; OsiriX Imaging Software, Geneva, Switzerland). The analysis of coronary 18F-178 
fluoride activity has been described previously (6, 7). In brief, visual assessment for 179 
increased coronary 18F-fluoride activity was performed on both a per-patient level and per-180 
segment basis. For a signal to be co-localised to the coronary artery, an atherosclerotic plaque 181 
had to be present on the CCTA and the increased pattern of radiotracer had to arise from the 182 
coronary artery and follow its course over >5 mm in three dimensions on orthogonal views. 183 
Semi-quantitative PET analysis was undertaken for all proximal coronary segments in 184 
addition to any atherosclerotic segment with focal 18F-fluoride activity as described above. 185 
Maximum standardized uptake values (SUVMAX) were measured within regions of interest. 186 
Correction was made for uptake in a referent proximal coronary plaque with no evidence of 187 
increased 18F-fluoride activity. To calculate coronary target to background ratios (TBR), 188 
coronary SUVMAX was divided by these background measures providing TBRMAX. Coronary 189 
18F-fluoride activity with TBRMAX >1.25 was classified a high-risk plaque. 190 
 191 
High-sensitivity cardiac troponin I 192 
Plasma high-sensitivity cardiac troponin I concentrations were measured using the 193 
ARCHITECTSTAT assay (Abbott Laboratories, Abbott Park, Illinois). The limit of detection is 194 
1.0 ng/L with an inter-assay co-efficient of variation <10% at 4.7 ng/L (9). The upper 195 
reference limit (99th centile) based on 4,590 samples from healthy men and women is 34 ng/L 196 
for men and 16 ng/L for women (10). Samples were collected at baseline, 30 days and 3, 6, 9 197 
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and 12 months. A value of 0.5 ng/L was imputed for troponin values below the limit of 198 
detection.  199 
 200 
Platelet function analysis 201 
Platelet and monocyte activation in response to adenosine diphosphate (ADP) was 202 
determined by flow cytometry, as described previously (11). These analyses were performed 203 
by a single technician blinded to study allocation with the results of these investigations 204 
withheld from the study team until after trial database lock. Briefly, peripheral venous blood 205 
was obtained from all participants at the baseline and 1-month visits. Blood was drawn by 206 
clean venepuncture of a large antecubital vein using a 19-gauge needle, and care was taken to 207 
ensure a smooth blood draw without venous stasis. Blood was collected into tubes containing 208 
the direct thrombin inhibitor, D-Phenylalanine-L-prolyl-L-arginine chloromethyl ketone 209 
(PPACK, Cambridge Biosciences). Tubes were gently inverted to ensure mixing of whole 210 
blood with anticoagulant.  211 
 212 
Immunolabelling and flow cytometry were performed in whole blood to avoid centrifugation 213 
and washing steps which can lead to artefactual platelet activation. All chemicals were 214 
obtained from BD Biosciences. (Oxford, UK). Aliquots of whole blood (50 μL) were 215 
incubated with anti-CD14-Allophycocyanin (APC), anti-CD42a-fluorescein isothiocyanate 216 
(FITC), anti-CD11b-PE-Cyanine(Cy)7, anti-CD62p-Phycoerythrin (PE) and isotype matched 217 
controls for 20 min at room temperature in Eppendorfs with and without ADP (at final 218 
concentration of 20 µmol/L). Thereafter, samples were fixed with 1% paraformaldehyde (p-219 
selectin) or FACS-Lyse (platelet-monocyte aggregates). All samples were analysed within 24 220 
hours using a FACSCalibur flow cytometer (Becton-Dickinson). Data analysis was 221 
performed using FlowJo v10 (Treestar, Oregon, USA). A medium flow setting was used to 222 
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minimize leukocyte-platelet coincident events. Monocytes were identified based on their 223 
forward and side scatter characteristics and then by triggering on FL-4 to identify CD14-PE 224 
positive monocytes and exclude large granular lymphocytes. For each measurement a 225 
minimum of 2,500 monocytes were collected. Platelet-monocyte aggregates were defined as 226 
monocytes positive for CD42a. All results are expressed as geometric mean of fluorescence. 227 
P-selectin expression was defined as CD42a-FITC positive platelets that were also positive 228 
for CD62p-PE. 229 
 230 
Study Endpoints 231 
The pre-specified primary endpoint was high-sensitivity cardiac troponin I concentrations at 232 
30 days in patients with increased coronary 18F-fluoride activity. Secondary endpoints were 233 
plasma high-sensitivity cardiac troponin I concentration at 30 days in patients without 234 
coronary 18F-fluoride activity, and plasma high-sensitivity troponin I concentration over 1 235 
year. Adverse events were recorded in all patients who received a single dose of study 236 
medication and included bleeding events categorized according to PLATO criteria as major 237 
life-threatening, other major, minor or minimal bleeding (3). 238 
 239 
Sample Size 240 
In patients with increased coronary 18F-fluoride uptake, we previously reported that mean 241 
troponin concentrations were more than double those in patients without increased coronary 242 
18F-fluoride uptake (7.9 [SD 9.3] vs. 3.1 [SD 1.9] ng/L, p=0.047) (7). It was estimated that 243 
ticagrelor would reduce troponin concentration by half. Forty-eight patients per treatment 244 
arm were required to achieve 80% power at two-sided p<0.05. After allowing for 15% drop-245 
out, we estimated that fifty-five patients will be required per treatment arm. Previous studies 246 
had found that 45% of patients with advanced but stable coronary artery disease 247 
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demonstrated increased coronary 18F-fluoride uptake, so a total sample size of 250 patients 248 
was estimated to be required to identify 110 patients with increased coronary 18F-fluoride 249 
activity. Termination of further recruitment could be authorized by the trial steering 250 
committee once a per-protocol population of 110 patients with increased coronary 18F-251 
fluoride activity had been randomized and completed the primary endpoint at 30 days. 252 
 253 
Statistical Analysis 254 
Categorical data are presented using counts and percentages, whilst continuous variables are 255 
presented using mean, standard deviation (SD), median, interquartile range, minimum, 256 
maximum, and number of patients. Participants were removed from formal statistical analysis 257 
where data were missing for that outcome variable. All (except safety) analyses were 258 
performed on a per-protocol population that excluded participants without a blood sample, or 259 
whose compliance was <80% for the study medication, at the 30-day visit. For the primary 260 
analysis, the change in troponin I concentration from baseline to 30 days was compared 261 
between the two treatment groups (ticagrelor and placebo) using linear regression, adjusting 262 
for the minimisation variables in patients with increased coronary 18F-fluoride uptake. Prior 263 
to analysis, tests for normality were undertaken and, where data were skewed, logarithmic 264 
transformation was performed. Central estimates and 95% confidence intervals (CI) were 265 
calculated. Similar analyses were performed for secondary outcomes. In post-hoc testing, we 266 
compared baseline troponin concentrations between patients with and without evidence of 267 
coronary 18F-fluoride activity and also confirmed treatment efficacy by comparison of ADP-268 
stimulated platelet activation between the two trial intervention groups (ticagrelor versus 269 
placebo). For 1-year evaluation of changes in cardiac troponin I concentrations, an adjusted 270 
linear regression model (adjusted for the minimisation variables) was generated and 271 
descriptive statistics were presented for the area under the curve. Where there were missing 272 
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values, the value was imputed linearly from adjacent measurements. Adjustment for age was 273 
performed as a linear term. To determine whether there was efficacy of ticagrelor using a 274 
baseline troponin I concentration ≥5 ng/L, a post-hoc comparison was made between groups 275 
using the method described in the primary analysis. For all analyses, a two-sided p<0.05 was 276 
taken as statistically significant. Statistical analysis was performed using SAS (Software 9.4, 277 
North Carolina) with the primary analysis validated by a second statistician in Edinburgh 278 
Clinical Trials Unit. Post-hoc analyses were performed separately from the primary statistical 279 
analysis plan using R version 3.4.0 (R Foundation for Statistical Computing, Vienna, Austria) 280 




Study Population 284 
A total of 361 patients were screened and 202 patients were randomized following the 285 
baseline coronary 18F-fluoride PET-CCTA (Figure 1). Eleven patients discontinued the 286 
study early due to withdrawal of consent (n=1), a new diagnosis of malignancy on baseline 287 
PET-CCTA (n=1), <80% compliance with study medication at 30 days (n=8), and a sudden 288 
unexpected death prior to receiving study medication (n=1). The randomized groups were 289 
well matched for the presence of cardiovascular risk factors and represented a high-risk 290 
cohort with 70% having a history of acute coronary syndrome (median 2.25 years prior to 291 
study enrolment) (Table 1). A per-protocol population of 191 patients (mean age 65.9, SD 292 
8.3 years, 80% male) had both blood sampling at 30 days and ≥80% compliance with the 293 
study medication, comprising 94 patients in the ticagrelor group and 97 patients in the 294 
placebo group. One hundred and twenty (62.8%) patients had evidence of coronary 18F-295 
fluoride activity in at least one epicardial vessel (Table 2, Figure 2).  296 
 297 
The geometric mean troponin I concentration at baseline was 3.8 (Geometric SD 2.9) ng/L in 298 
patients with increased coronary 18F-fluoride activity compared with 2.5 (Geometric SD 2.6) 299 
ng/L in those without uptake (p=0.004; Table 2) from a post-hoc analysis. 300 
 301 
Effect of ticagrelor on platelet function 302 
Baseline platelet and monocyte reactivities were well balanced between treatment arms. 303 
Consistent with its known pharmacological action, ticagrelor markedly inhibited platelet P-304 
selectin expression and reduced the formation of platelet-monocyte aggregates following ex 305 
vivo stimulation with ADP (Figure 3, p<0.001 for all). Ticagrelor had no effect on 30-day 306 
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unstimulated platelet activation (p>0.05 for all). These results were derived from post-hoc 307 
analysis. 308 
 309 
Effect of ticagrelor on high-sensitivity troponin I at 30 days 310 
For the primary endpoint, there was no effect of ticagrelor on troponin I at 30 days in patients 311 
who had increased coronary 18F-fluoride activity (ratio of geometric means ticagrelor versus 312 
placebo 1.11, 95% CI 0.90 to 1.36; p=0.32) (Table 3). Similarly, amongst the 71 (37.2%) 313 
patients without discernible coronary 18F-fluoride activity, there was no difference in the 30-314 
day troponin I concentration between ticagrelor and placebo (ratio of geometric means 1.02, 315 
95% CI 0.80 to 1.31; p=0.87) (Table 3). 316 
 317 
We explored whether a reduction in cardiac troponin I could be demonstrated over twelve 318 
months. Twelve-month troponin I concentrations were measured in 183 (95.8%) patients, 319 
comprising of 91 (96.8%) patients in the ticagrelor group and 92 (94.8%) patients in the 320 
placebo group. There was no difference in area under the concentration curve of troponin I 321 
over twelve months between the ticagrelor and placebo groups (ratio of geometric means 322 
0.92, 95% CI 0.74 to 1.13; p=0.42) (Figure 4) (Table 4). Post-hoc analysis of the subset of 323 
patients with a baseline troponin I concentration ≥5 ng/L (ticagrelor n=34, baseline geometric 324 
mean 10.3 ng/L; placebo n=33, baseline geometric mean 8.7 ng/L), found there was no 325 
change in troponin I concentration at 30 days (p=0.89) or twelve months (p=0.86). 326 
(Supplementary Figure 1, Supplementary Table 2). 327 
 328 
Safety outcomes 329 
There were no suspected unexpected serious adverse reactions over the course of this study. 330 
Serious adverse events occurred in 7/100 (7%) patients who received at least one single dose 331 
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of ticagrelor and 15/101 (11.9%) patients who were administered placebo (Supplementary 332 
Table 3). There were no reported major life-threatening or other major bleeding events over 333 
the course of this study. Minimal bleeding events (bruising) were reported in 64 (64.0%) 334 
patients in the ticagrelor group and 12 (11.9%) patients in the placebo group (Supplementary 335 
Table 4). Dyspnea episodes occurred in 24 (24%) patients in the ticagrelor group compared 336 




In this randomized placebo-controlled trial, we found no evidence that ticagrelor 90 mg twice 340 
daily reduces plasma high-sensitivity cardiac troponin I concentrations in patients with high-341 
risk plaque and established multivessel coronary artery disease. This suggests that, in patients 342 
with high-risk coronary plaque, plasma cardiac troponin I concentrations are not attributable 343 
to subclinical myocardial injury from thrombotic microembolic injury.  344 
 345 
Our study has several important strengths. This is the first trial to use PET-CCTA imaging 346 
with 18F-fluoride to identify patients with high-risk coronary plaque who may be at 347 
heightened risk of future coronary events and thereby have the most to gain from potent dual 348 
antiplatelet therapies. It is also the largest trial to date employing coronary plaque PET 349 
imaging. Whilst previous PET studies have used 18F-fluorodeoxyglucose to visualise 350 
inflammation within the carotid arteries as a surrogate to guide intensification of 351 
atherosclerotic therapy (12, 13), the coronary and cerebral vascular beds differ both with 352 
respect to their underlying molecular pathophysiology and also in response to the treatment 353 
effect using ticagrelor (3, 14). Second, our unique study design enabled high-risk patients 354 
with multivessel coronary disease and in vivo evidence of disease activity to be precisely 355 
phenotyped prior to randomization in a manner that can seldom be achieved in larger clinical 356 
outcome trials (3, 15). Finally, this is the first prospective randomized controlled trial to use 357 
high-sensitivity cardiac troponin I concentrations as a surrogate outcome measure for 358 
assessing future cardiovascular risk. 359 
 360 
In trying to understand why P2Y12 inhibition did not reduce cardiac troponin in this study, it 361 
is worth addressing some of the underlying assumptions in the trial design. Does coronary 362 
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18F-fluoride activity identify patients with high-risk plaque? Recent studies have found that 363 
18F-fluoride holds potential in identifying culprit plaques in the coronary circulation by 364 
classifying patients who have a high-risk cardiovascular phenotype and culprit plaque rupture 365 
following type 1 myocardial infarction (6, 7). Histological validation indicates that 18F-366 
fluoride preferentially binds to microcalcification in regions of plaque mineralisation, a key 367 
component of high-risk plaque (16). Hydroxyapatite, the most common form of 368 
atherosclerotic microcalcification, is extruded from apoptotic macrophages, and accumulates 369 
within necrotic cores where it may destabilise the structural integrity of the fibrous cap (17, 370 
18). The identification of abnormal material composition of the arterial wall has clinical 371 
relevance, as these regions may lead to atherosclerotic plaque rupture manifesting as 372 
myocardial infarction, stroke or aneurysm rupture (7, 19, 20). In our cohort, the frequency of 373 
18F-fluoride activity (>60%) in stable coronary artery disease is similar to previous estimates 374 
in patients with a high burden of coronary artery disease and prior myocardial infarction (6). 375 
This work confirms the high prevalence of coronary 18F-fluoride activity in stable patients 376 
with multivessel coronary artery disease in whom intensification of antiplatelet therapy may 377 
be considered. 378 
 379 
A key question is whether troponin measurement below the 99th centile reflects subclinical 380 
plaque rupture with accompanying distal microvascular embolisation as has previously been 381 
posited (21). In this regard, some therapies directed at reducing the risk of atherosclerotic 382 
plaque rupture, such as pravastatin, both modify troponin concentrations and reduce the risk 383 
of myocardial infarction (22, 23). In contrast, strategies that have failed to demonstrate a 384 
reduction in cardiovascular events in the context of stable coronary artery disease, such as 385 
coronary revascularisation, attenuation of plaque inflammation and inhaled therapies for 386 
respiratory disease, have not correlated with a reduction in serial troponin concentration (24, 387 
 20 
25, 26). If subclinical plaque thrombosis is the dominant mechanism underlying detectable 388 
troponin I concentrations in patients with stable coronary artery disease, a reduction in 389 
troponin I concentration would be expected following the administration of potent antiplatelet 390 
therapy. The lack of response to ticagrelor in this study would suggest that other contributing 391 
mechanisms to myocardial injury should be considered. The emergence of newer therapies 392 
(such as sodium/glucose cotransporter 2 inhibition) that lower blood pressure may reduce 393 
troponin concentrations through an improvement in myocardial remodelling, further raising 394 
doubts over the subclinical plaque rupture hypothesis (27, 28). In this study, high-sensitivity 395 
cardiac troponin I concentrations were higher in patients with 18F-fluoride activity, albeit the 396 
differences were small and below the established risk stratification threshold of 5 ng/L (9, 22, 397 
29). Therefore, it seems unlikely that troponin at these concentrations reflects subclinical 398 
plaque rupture and it is perhaps unsurprising that ticagrelor treatment did not result in an 399 
early or late reduction in troponin concentration. 400 
 401 
Previous reports have suggested that there is a high incidence of subclinical intracoronary 402 
thrombus in patients with apparently stable coronary artery disease. Indeed, some have 403 
suggested that this occurs in as many as one in seven patients (8). If this is the case, it would 404 
appear that intracoronary thrombus does not track with troponin. This suggests we require 405 
better non-invasive markers of coronary thrombosis, such as novel PET tracers (30) or non-406 
invasive imaging (31), to use as biomarkers of cardiovascular risk and anti-thrombotic 407 
therapeutic efficacy. 408 
 409 
There are some study limitations that we should acknowledge. This study had a modest 410 
sample size to assess the impact of ticagrelor on a readily available plasma biomarker, and a 411 
larger study would be required to assess clinical outcomes of ticagrelor use in patients with 412 
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stable coronary artery disease and coronary 18F-fluoride activity. The low baseline troponin I 413 
concentrations observed in this study may have limited power to demonstrate the benefit of 414 
ticagrelor in this population. Enrichment of the population by selecting patients with higher 415 
troponin I concentrations prior to study entry may need to be considered for future trials. It 416 
should also be acknowledged that this study was undertaken in a single centre with expertise 417 
in coronary 18F-fluoride imaging and the methods for analysing coronary 18F-fluoride 418 
activity are subject to a number of operator and scan-dependent variables. Whilst recent 419 
reports have suggested that coronary 18F-fluoride activity may hold prognostic value in 420 
stratifying high-risk populations (32), larger prospective studies evaluating the prognostic 421 
utility of coronary 18F-fluoride activity in patients with cardiovascular disease are ongoing 422 
(NCT02278211).  423 
 424 
Conclusions 425 
In patients with multivessel coronary artery disease and in vivo coronary 18F-fluoride activity, 426 
we found no evidence that intensification of antiplatelet therapy using ticagrelor 90 mg twice 427 
daily reduces plasma high-sensitivity cardiac troponin I concentration at 30 days or 1 year. 428 
These findings suggest that in this group of patients plasma high-sensitivity cardiac troponin I 429 
concentrations may not be a suitable marker to predict efficacy of P2Y12 inhibition.  430 
  431 
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Clinical Perspectives 432 
 433 
Competency in Medical Knowledge: High-risk coronary artery plaque and plasma high-434 
sensitivity cardiac troponin I concentrations are associated with increased rates of 435 
cardiovascular events. 436 
 437 
Competency in Patient Care: Patients with stable coronary artery disease and an increased 438 
risk of cardiovascular events may benefit from extended therapy with P2Y12 inhibition. 439 
 440 
Translational Outlook 1: Although this study used an early biomarker (30-day plasma high-441 
sensitivity cardiac troponin I concentration) to evaluate drug efficacy, coronary 18F-fluoride 442 
activity does not appear to be useful in identifying patients who may benefit from extended 443 
P2Y12 inhibition. 444 
 445 
Translational Outlook 2: A detailed phenotype of coronary plaque disease activity using 446 
positron emission tomography is both feasible and practical in the setting of a randomized 447 
placebo-controlled trial. 448 
  449 
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Table 1.  
 














































P value (ticagrelor 
versus placebo)¶ 
Age, years 65.9±8.2 65.9±8.3 65.5±8.4 66.3±8.1 0.504 
Male  162 (80) 152 (80) 74 (79) 78 (80) 0.912 
Body Mass Index, kg/m2 29.8±5.2 29.7±5.0 30.0±5.2 29.4±4.9 0.413 
Medical history      
History of acute coronary syndrome 143 (71) 134 (70) 65 (69) 69 (71) 0.887 
Days between ACS and randomisation*  821 (620, 1056) 821 (625, 1037) 800 (620, 970) 861 (646,1081)  
Percutaneous Coronary Intervention 163 (81) 154 (81) 75 (80) 79 (81) 0.915 
Coronary Artery Bypass Grafting 40 (20) 38 (20) 18 (19) 20 (21) 0.942 
Hypertension  113 (56) 105 (55) 52 (55) 53 (55) 1.000 
Hypercholesterolaemia 195 (97) 185 (97) 93 (99) 92 (95) 0.228 
Diabetes Mellitus  39 (19) 36 (19) 19 (20) 17 (18) 0.772 
Prior Stroke/Transient Ischemic Attack  4 (2) 4 (2) 2 (2) 2 (2) 1.000 
 31 
History of Atrial Fibrillation  5 (2) 5 (3) 4 (4) 1 (1) 0.346 
Peripheral Vascular Disease  8 (4) 7 (4) 1 (1) 6 (6) 0.134 
Medications      
Aspirin  202 (100) 191 (100) 94 (100) 97 (100) NA 
Statin  192 (95) 182 (95) 92 (98) 90 (93) 0.188 
Beta-Blocker  138 (68) 130 (68) 66 (70) 64 (66) 0.637 
Angiotensin Converting Enzyme 
Inhibitor/Angiotensin II Receptor 
Blocker  
155 (77) 145 (76) 68 (72) 77 (79) 
0.333 
Hemoglobin, g/dL 14.0±1.3) 14.0±1.3 14.2±1.2 13.8±1.3 0.034 





  31-60 23 (11) 22 (12) 9 (10) 13 (13)  
   >60 179 (89) 169 (88) 85 (90) 84 (87)  

















Values are n (%) or mean±standard deviation 
* median (interquartile range) 
¶ Post-hoc analysis 
 
 
High density lipoprotein, mg/dL 46±12 46±12 43±15 46±12 0.128 
Low density lipoprotein, mg/dL 89 ±31 89±31 85±35 89±27 0.377 
Triglycerides, mg/dL 159±97 151±97 159±106 151±80 0.556 
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Table 2.  











Coronary 18F-Fluoride Uptake   
N 120 59 61  
Baseline 3.8±2.9 4.2±2.9 3.5±3.0 0.197 
30 days 3.6±2.7 4.1±2.5 3.2±2.9 0.072 
Ratio of 30 days to baseline 0.95±1.87 0.97±2.13 0.93±1.59 0.907 
No Coronary 18F-Fluoride Uptake  
N 71 35 36  
Baseline 2.5±2.6 2.5±2.8 2.4±2.4 0.872 
30 days 2.4±2.7 2.4±2.8 2.3±2.6 0.877 
Ratio of 30 days to baseline 0.97±1.68 0.97±1.77 0.96±1.59  
 
Geometric mean and geometric standard deviation, back transformed from log transformed 
values. 




Table 3.  
Plasma high-sensitivity cardiac troponin I concentration (ng/L) at 30 days for the per-
protocol population 
 
 Adjusted Geometric Mean 
(GSE) 
Ratio of Geometric Means  
 Ticagrelor Placebo (95% CI) p-valve 
Cardiac troponin I, ng/L 
(18F-fluoride activity) 
3.8 (1.1) 3.4 (1.1) 1.11 (0.90 to 1.36) 0.32 
Cardiac Troponin I, ng/L 
(No 18F-fluoride activity) 
2.4 (1.1) 2.3 (1.1) 1.02 (0.80 to 1.31) 0.87 
 
Estimates are back transformed estimates from analysis of log transformed values at 
30 days adjusting for age, sex and log transformed baseline troponin. Ratio of 
geometric means is Ticagrelor divided by Placebo. GSE, geometric standard error. 
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Table 4.  
Plasma high-sensitivity cardiac troponin I concentration over 1 year for participants in 
per protocol population 
 
 Adjusted Geometric Mean 
(GSE) 
Ratio of Geometric Means  
 Ticagrelor Placebo (95% CI) p-valve 
AUC from 30 days to 
1 year 
(18F-fluoride activity) 
3.7 (1.1) 4.4 (1.1) 0.86 (0.63 to 1.17) 0.33 
AUC from 30 days to 
1 year 
(No 18F-fluoride activity) 
2.4 (1.1) 2.3 (1.1) 1.04 (0.84 to 1.28) 0.70 
 
Estimates are back transformed estimates from analysis of log transformed values 
area under curve from 30 days to 1 year adjusting for age, sex and log transformed 
baseline troponin. Ratio of geometric means is Ticagrelor divided by Placebo. AUC, 
area under curve, ng/L, GSE, geometric standard error. 
  
 36 
Central Illustration. Using coronary 18F-fluoride to identify patients who may 
benefit from intensified dual antiplatelet therapy. 
Coronary 18F-fluoride positron emission tomography was used to identify high-risk 
coronary plaque in patients with stable multivessel coronary artery disease. 
Randomization to intensified dual antiplatelet therapy with ticagrelor did not reduce 
plasma high-sensitivity cardiac troponin I concentrations at 30-days in patients with 
high-risk plaque.  
 
Figure 1. Consort Diagram. 
Flow diagram of the progress through the phases of the randomized trial between 
ticagrelor and placebo groups. 
 
Figure 2. Intracoronary thrombus and coronary 18F-fluoride activity. 
A 72-year-old female with intracoronary thrombus in the left main stem (A, B arrow). 
Axial reconstructions demonstrate a non-obstructive intracoronary thrombus at 11 
o’clock with coronary calcification at 2 o’clock and 7 o’clock (C and D, schematic). 
18F-Fluoride activity was present in the coronary plaque (E and F, schematic).  
 
Figure 3. Flow cytometry assessment of platelet activation at baseline and 30 days. 
Unstimulated (upper panels) and adenosine diphosphate (20 µmol/L) stimulated 
(lower panels) levels of (a) platelet activation (P-selectin expression) and (b) platelet-
monocyte aggregates. 
 
Figure 4. Plasma high-sensitivity cardiac troponin I concentration over 1 year. 
 37 
Box-whisker plot of individual patient-level plasma high-sensitivity troponin I 
concentration (ng/L) in ticagrelor (blue) and placebo (red) groups at baseline, 1, 3, 6, 
9 and 12 months. Median and interquartile range for each time point. 
 
Ticagrelor to reduce myocardial injury in patients 
with high-risk coronary artery plaque 
Supplementary Appendix 
  
Supplementary Table 1. 
Inclusion and Exclusion Criteria 
 
Inclusion Criteria 
For inclusion in the study subjects should fulfil the following criteria: 
1. Patients aged ≥40 years with angiographically proven multivessel coronary 
artery disease defined as at least two major epicardial vessels with any 
combination of either (a) >50% luminal stenosis, or (b) previous 
revascularization (percutaneous coronary intervention or coronary artery 
bypass graft surgery). 
2. Provision of informed consent prior to any study specific procedures 
3. Receiving aspirin 
Exclusion Criteria 
Subjects should not enter the study if any of the following exclusion criteria are 
fulfilled: 
1. An acute coronary syndrome within the last 12 months 
2. An indication for dual anti-platelet therapy, such as drug eluting stent 
3. Receiving thienopyridine therapy such as clopidogrel or prasugrel 
4. Percutaneous coronary intervention or coronary artery bypass graft surgery 
within the last 3 months 
5. Inability or unwilling to give informed consent 
6. Women who are pregnant, breastfeeding or of child-bearing potential (women 
who have experienced menarche, are pre-menopausal and have not been 
sterilised) will not be enrolled into the trial 
7. Known hypersensitivity to ticagrelor or one of its excipients 
8. Active pathological bleeding or bleeding diathesis 
9. Significant thrombocytopenia: platelets <100 x 109 /L 
10. History of intracranial hemorrhage 
11. Moderate to severe liver impairments (Child’s Grade B or C) 
12. Maintenance therapy with strong CYP3A4 inhibitors, such as ketoconazole, 
nefazodone, ritonavir, indinavir, atazanavir, or clarithromycin 
13. Major intercurrent illness of life expectancy <1 year 
14. Renal dysfunction (eGFR ≤30 mL/min/1.73m2) 
15. Contraindication to iodinated contrast agents 
16. Planned coronary revascularization or major non-cardiac surgery in the next 
12 months 
17. Maintenance therapy with simvastatin or lovastatin at doses greater than 40mg 
daily 




Supplementary Table 2. 
Post-hoc analysis of efficacy of Ticagrelor in patients with troponin I concentration ≥ 
5 ng/L 
 
PLACEBO Baseline 18F-fluoride uptake on PET-CT 
 Negative Negative Positive Positive 
 
Baseline hs-
cTnI <5 ng/L 
Baseline hs-
cTnI ≥5 ng/L 
Baseline hs-
cTnI <5 ng/L 
Baseline hs-
cTnI ≥5 ng/L 
Baseline hs-
cTnI, geometric 
mean (95% CI) 
1.8 
(1.4 to 2.3) 
7.7 
(5.9 to 10.1) 
1.8 
(1.4 to 2.3) 
9.3 
(7.2 to 12.1) 




(1.3 to 2.3) 
7.1 
(4.1 to 12.1) 
1.8 
(1.4 to 2.3) 
8.3 
(6.1 to 11.2) 
 
TICAGRELOR Baseline 18F-fluoride uptake on PET-CT 
 Negative Negative Positive Positive 
 
Baseline hs-
cTnI <5 ng/L 
Baseline hs-
cTnI >5 ng/L 
Baseline hs-
cTnI <5 ng/L 
Baseline hs-





(1.4 to 2.3) 
8.7 
(4.7 to 16.3) 
2.3 
(1.9 to 2.9) 
10.3 
(7.6 to 15.8) 




(1.3 to 2.2) 
10.2 
(5.2 to 20.1) 
2.7 
(2.1 to 3.4) 
8.3 
(6.1 to 11.2) 
 
  
Supplementary Table 3. 
Serious Adverse Events for safety population 
 




















 10 7 (7%) 15 12 (11.9%) 25 19 (9.5%) 
Outcome Resolved 10 7 (7%) 15 12 (11.9%) 25 19 (9.5%) 
Causality Unrelated to 
IMP & NIMP 
9 7 (7%) 14 11 (10.9%) 23 18 (9%) 
Unrelated to 
IMP 
1 1 (1%) 1 1 (1%) 2 2 (1%) 
Expectedness Expected 0 0 (0%) 0 0 (%) 0 0 (0%) 
Unexpected 10 7 (7%) 15  12 (11.9%) 25 19 (9.5%) 
Severity Mild 5 5 (5%) 5 4 (4%) 10 9 (4.5%) 
Moderate 5 3 (3%) 9 9 (8.9%) 14 12 (6%) 
Severe 0 0 (0%) 1 1 (1%) 1 1 (0.5%) 
  
  
Supplementary Table 4.  
Bleeding and Dyspnea events for safety population 
 


















Any bleeding event 88 64 (64%) 14 12 (11.9%) 102 76 (37.8%) 
PLATO 
classification 
Minimal 87 64 (64%) 14 12 (11.9%) 101 76 (37.8%) 
Minor 1 1 (1%) 0 0 (0%) 1 1 (0.5%) 
Major 0 0 (0%) 0 0 (0%) 0 0 (0%) 
Major life 
threatening 
0 0 (0%) 0 0 (0%) 0 0 (0%) 
Dyspnea At 1 year 27 24 (24%) 8 8 (7.9%) 35 32 (15.9%) 
 
  
Supplementary Table 5.  
Post-hoc analysis of plasma high-sensitivity cardiac troponin I concentration (ng/L) in 









Coronary 18F-Fluoride Uptake  
N 127 62 65 
Baseline 3.8±2.9 4.2±2.9 3.5±2.9 
30 days 3.7±2.7 4.2±2.5 3.3±2.9 
Ratio of 30 days to baseline 0.97±1.86 1.00±2.12 0.95±1.59 
No Coronary 18F-Fluoride Uptake 
N 72 36 36 
Baseline 2.4±2.5 2.5±2.7 2.4±2.4 
30 days 2.3±2.7 2.4±2.8 2.3±2.6 
Ratio of 30 days to baseline 0.96±1.68 0.96±1.77 0.96±1.59 
 
Geometric mean and geometric standard deviation, back transformed from log transformed 
values. 
  
Supplementary Table 6.  
Post-hoc analysis of plasma high-sensitivity cardiac troponin I concentration (ng/L) at 
30 days for the intention to treat population 
 
 Adjusted Geometric Mean 
(GSE) 
Ratio of Geometric Means  
 Ticagrelor Placebo (95% CI) p-value 
Cardiac troponin I, ng/L 
(18F-fluoride activity) 
3.9 (1.1) 3.5 (1.1) 1.12 (0.92 to 1.36) 0.26 
Cardiac Troponin I, ng/L 
(No 18F-fluoride activity) 
2.3 (1.1) 2.3 (1.1) 1.00 (0.78 to 1.29) 0.98 
 
Estimates are back transformed estimates from analysis of log transformed values at 
30 days adjusting for age, sex and log transformed baseline troponin. Ratio of 
geometric means is Ticagrelor divided by Placebo. GSE, geometric standard error. 
  
Supplementary Table 7.  
Post-hoc analysis of plasma high-sensitivity cardiac troponin I concentration over 1 
year for participants in intention to treat population 
 
 Adjusted Geometric Mean 
(GSE) 
Ratio of Geometric Means  
 Ticagrelor Placebo (95% CI) p-value 
AUC from 30 days to 
1 year 
(18F-fluoride activity) 
3.7 (1.1) 4.3 (1.1) 0.87 (0.64 to 1.17) 0.35 
AUC from 30 days to 
1 year 
(No 18F-fluoride activity) 
2.4 (1.1) 2.3 (1.1) 1.04 (0.84 to 1.28) 0.70 
 
Estimates are back transformed estimates from analysis of log transformed values 
area under curve from 30 days to 1 year adjusting for age, sex and log transformed 
baseline troponin. Ratio of geometric means is Ticagrelor divided by Placebo. AUC, 
area under curve, ng/L, GSE, geometric standard error.  
Supplementary Figure 1. Plasma high-sensitivity cardiac troponin I concentration 
(stratified population with troponin I >5ng/L at baseline) over 1 year. 
 
Box-whisker plot of individual patient-level plasma high-sensitivity troponin I 
concentration (ng/L) in ticagrelor (blue) and placebo (red) groups at baseline, 1, 3, 6, 
9 and 12 months (p=ns for all values). Median and interquartile range for each time 
point. 
 
 
